

Antithrombotic Therapy for Atrial Fibrillation with Stable

New England Journal of Medicine

381, 2479-2481

DOI: [10.1056/nejmc1914049](https://doi.org/10.1056/nejmc1914049)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Rivaroxaban monotherapy for AF and stable CAD. Nature Reviews Cardiology, 2019, 16, 646-646. | 6.1 | 0 |
| 2 | Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471989168. | 1.0 | 6 |
| 3 | Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more. Journal of Thrombosis and Thrombolysis, 2020, 49, 321-324. | 1.0 | 3 |
| 4 | Atrial fibrillation and ischaemic heart disease: should we use acetylsalicylic acid beside anticoagulants?. European Heart Journal Supplements, 2020, 22, L166-L169. | 0.0 | 4 |
| 6 | Real-Life Incident Atrial Fibrillation in Outpatients with Coronary Artery Disease. Journal of Clinical Medicine, 2020, 9, 2367. | 1.0 | 4 |
| 7 | Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines. Journal of Clinical Medicine, 2020, 9, 3474. | 1.0 | 15 |
| 9 | Complex clinical scenarios with the use of direct oral anticoagulants in patients with atrial fibrillation: a multidisciplinary expert advisory board. Netherlands Heart Journal, 2020, 28, 504-513. | 0.3 | 1 |
| 10 | The management of atrial fibrillation in heart failure: an expert panel consensus. Heart Failure Reviews, 2020, 26, 1345-1358. | 1.7 | 15 |
| 11 | Antithrombotic treatment strategies after PCI. Lancet, The, 2020, 395, 866-867. | 6.3 | 0 |
| 12 | Importance of Atrial Fibrillation in Heart Failure Patients With Preserved Ejection Fraction Without Coronary Artery Disease. Circulation Journal, 2020, 84, 374-375. | 0.7 | 0 |
| 13 | Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2019. American Journal of Medicine, 2020, 133, 789-794. | 0.6 | 0 |
| 14 | A predictive nomogram of bleeding risk in patients with atrial fibrillation after drug-eluting stent implantation. Annals of Translational Medicine, 2021, 9, 193-193. | 0.7 | 1 |
| 15 | Management of Antithrombotic Therapy after Acute Coronary Syndromes. New England Journal of Medicine, 2021, 384, 452-460. | 13.9 | 66 |
| 16 | Overview of the 84 th Annual Scientific Meeting of the Japanese Circulation Society—Change Practice! â€•. Circulation Journal, 2021, 85, 323-329. | 0.7 | 0 |
| 18 | Antiplatelet Therapy And Percutaneous Coronary Interventions. Current Cardiology Reviews, 2021, 17, 232-243. | 0.6 | 0 |
| 19 | Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics. Journal of Thrombosis and Thrombolysis, 2022, 53, 436-445. | 1.0 | 8 |
| 20 | Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Endoscopy, 2021, 53, 947-969. | 1.0 | 47 |
| 21 | Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Gut, 2021, 70, 1611-1628. | 6.1 | 61 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 22 | Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis. <i>EuroIntervention</i> , 2021, 17, 550-560. | 1.4 | 31 |
| 23 | Very Late Stent Thrombosis After Discontinuation of Antiplatelet Agents During Anticoagulation Therapy in a Patient with Peri-stent Contrast Staining After Implantation of a Second-generation Drug-eluting Stent. <i>Internal Medicine</i> , 2022, , . | 0.3 | 1 |
| 24 | Efficacy and safety of an antithrombotic regimen for atrial fibrillation patients with acute coronary syndrome or those undergoing percutaneous coronary intervention: a meta-analysis. <i>Aging</i> , 2020, 12, 12930-12942. | 1.4 | 1 |
| 25 | Aspirin for primary prevention of atherosclerotic cardiovascular events. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 300-311. | 0.6 | 8 |
| 26 | Mechanisms of ST-segment elevation myocardial infarction in patients with atrial fibrillation, prior stenting and long-standing chronic coronary syndrome. <i>Cardiology Journal</i> , 2020, 27, 8-15. | 0.5 | 5 |
| 27 | Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020907. | 1.6 | 5 |
| 28 | Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, , 1. | 1.0 | 0 |
| 29 | Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 69-81. | 0.9 | 0 |
| 30 | The year in cardiology: arrhythmias and pacing. <i>SA Heart Journal</i> , 2020, 17, . | 0.0 | 0 |
| 31 | To drop or not to drop the antiplatelet agent, that is the question for patients with atrial fibrillation and chronic coronary syndrome undergoing percutaneous coronary intervention. <i>Cardiology Journal</i> , 2020, 27, 1-3. | 0.5 | 1 |
| 32 | For Primary Prevention, Should All Moderate- to High-Risk Patients Be Considered Candidates for Acetylsalicylic Acid?. <i>Canadian Journal of Hospital Pharmacy</i> , 2020, 73, . | 0.1 | 0 |
| 33 | Comparison of Long-Term Outcomes Between Combination Antiplatelet and Anticoagulant Therapy and Anticoagulant Monotherapy in Patients With Atrial Fibrillation and Left Atrial Thrombi. <i>Circulation Reports</i> , 2020, 2, 457-465. | 0.4 | 0 |
| 34 | Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology. <i>European Journal of Epidemiology</i> , 2021, 36, 1103-1109. | 2.5 | 1 |
| 35 | The 2020 CCS atrial fibrillation guidelines for pharmacists: Top 10 takeaways. <i>Canadian Pharmacists Journal</i> , 2022, 155, 171516352110581. | 0.4 | 1 |
| 36 | 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2021, 37, 1389-1426. | 0.5 | 38 |
| 37 | Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORPâ€™AF Longâ€™term General Registry. <i>European Journal of Clinical Investigation</i> , 2021, , e13709. | 1.7 | 0 |
| 38 | 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. <i>Thrombosis and Haemostasis</i> , 2022, 122, 020-047. | 1.8 | 192 |
| 39 | Management of stable coronary artery disease and atrial fibrillation with anti-thrombotic therapy. <i>Medicine (United States)</i> , 2021, 100, e27498. | 0.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 40 | Should we give triple therapy to patients with atrial fibrillation after percutaneous intervention?. Cleveland Clinic Journal of Medicine, 2020, 87, 599-601. | 0.6 | 0 |
| 41 | Monotherapy for nonvalvular A-fib with stable CAD?. , 2021, 70, 403-407. | | 0 |
| 43 | Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2022, 11, 512. | 1.0 | 3 |
| 44 | CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022. Cardiovascular Intervention and Therapeutics, 2022, 37, 1-34. | 1.2 | 62 |
| 45 | Atherosclerosis and Atrial Fibrillation: Double Trouble. Current Cardiology Reports, 2022, 24, 67-73. | 1.3 | 3 |
| 46 | Triple Antithrombotic Therapy (Triple Therapy) After Percutaneous Coronary Intervention in Chronic Anticoagulation: A Literature Review. Cureus, 2022, 14, e21810. | 0.2 | 5 |
| 47 | 2021 ESC/EACTS Guidelines for the management of valvular heart disease. EuroIntervention, 2022, 17, e1126-e1196. | 1.4 | 161 |
| 48 | Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations. JACC Asia, 2022, 2, 1-18. | 0.5 | 15 |
| 49 | A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes. Cmaj, 2022, 194, E205-E215. | 0.9 | 4 |
| 50 | The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial. BMC Medicine, 2022, 20, 69. | 2.3 | 0 |
| 51 | <scp>JCS</scp>/<scp>JHRS</scp> 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Journal of Arrhythmia, 2022, 38, 833-973. | 0.5 | 8 |
| 52 | Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives. Cardiovascular Intervention and Therapeutics, 2022, 37, 255-263. | 1.2 | 14 |
| 53 | Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome. International Journal of General Medicine, 2022, Volume 15, 2397-2414. | 0.8 | 3 |
| 54 | Trends and Outcomes of Oral Anticoagulation With Direct Current Cardioversion for Atrial Fibrillation/Flutter at an Academic Medical Center. Cardiology Research, 2022, 13, 88-96. | 0.5 | 3 |
| 55 | Efficacy and safety of direct oral anticoagulants with and without Aspirin: A systematic review and Meta-analysis. IJC Heart and Vasculature, 2022, 40, 101016. | 0.6 | 4 |
| 56 | Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a study protocol of the OPTIMA-AF trial. BMJ Open, 2021, 11, e048354. | 0.8 | 2 |
| 58 | Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. European Heart Journal, 2022, 43, 2442-2460. | 1.0 | 43 |
| 60 | ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes. European Heart Journal Supplements, 2022, 24, C254-C271. | 0.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 61 | Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1584-1593. | 1.8 | 5 |
| 62 | Management of antithrombotic therapy in patients at high bleeding risk after percutaneous coronary intervention for acute coronary syndromes: a case report. <i>European Heart Journal - Case Reports</i> , 2022, 6, . | 0.3 | 0 |
| 63 | Variation in heart rate range by 24h Holter monitoring predicts heart failure in patients with atrial fibrillation. <i>ESC Heart Failure</i> , 2022, 9, 3092-3100. | 1.4 | 2 |
| 64 | A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series. <i>Journal of Clinical Medicine</i> , 2022, 11, 4089. | 1.0 | 0 |
| 65 | Optimal Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Focused Review on High Bleeding Risk. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 1409-1420. | 0.9 | 11 |
| 66 | Clinical utility of the BIWACO score for patients with atrial fibrillation after percutaneous coronary intervention. <i>Heart and Vessels</i> , 0, , . | 0.5 | 0 |
| 67 | Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories. <i>JACC Asia</i> , 2022, 2, 882-893. | 0.5 | 1 |
| 68 | Dual-antithrombotic therapy and gastroprotection in atrial fibrillation: An observational primary care study. <i>BJGP Open</i> , 0, , BJGPO.2022.0048. | 0.9 | 0 |
| 69 | Stroke Prevention in Atrial Fibrillation. <i>JACC Asia</i> , 2022, 2, 395-411. | 0.5 | 8 |
| 70 | Apixaban versus No Anticoagulation by P2Y12 Inhibitor Prescription Status in Dialysis Patients with Atrial Fibrillation. <i>Kidney360</i> , 2022, 3, 1769-1771. | 0.9 | 2 |
| 71 | Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, . | 1.1 | 1 |
| 72 | Incidence, Timing, and Causes of Late Bleeding After TAVR in an Asian Cohort. <i>JACC Asia</i> , 2022, 2, 622-632. | 0.5 | 3 |
| 73 | Dual therapy with oral anticoagulation and single antiplatelet agent versus monotherapy with oral anticoagulation alone in patients with atrial fibrillation and stable ischemic heart disease: a systematic review and meta-analysis. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2023, 66, 493-506. | 0.6 | 3 |
| 74 | Comparison of Efficacy and Safety of Anticoagulant Monotherapy and Combined Therapy of Anticoagulant and Antiplatelets in Patients With Stable Coronary Artery Disease and Atrial Fibrillation: A Meta-Analysis. <i>Cureus</i> , 2022, , . | 0.2 | 0 |
| 75 | Efficacy and safety of oral anticoagulants in elderly patients with stable coronary artery disease and atrial fibrillation. <i>Thrombosis Journal</i> , 2022, 20, . | 0.9 | 2 |
| 76 | Cardiovascular and renal protective effects of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation. <i>PLoS ONE</i> , 2022, 17, e0275103. | 1.1 | 2 |
| 77 | Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis. <i>Journal of the American Heart Association</i> , 2022, 11, . | 1.6 | 1 |
| 78 | Rationale and Design of Registry for Estimation of Warfarin and Rivaroxaban in Atrial Fibrillation Patients With Coronary Stent Implantation (REWRAPS). <i>Circulation Reports</i> , 2022, , . | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 79 | Combination of antiplatelet and anticoagulant therapy, component network meta-analysis of randomized controlled trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, . | 1.1 | 7 |
| 80 | Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease. <i>Journal of Interventional Cardiology</i> , 2022, 2022, 1-10. | 0.5 | 0 |
| 81 | Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients. <i>JACC Asia</i> , 2022, 2, 894-896. | 0.5 | 0 |
| 82 | Trend of anticoagulant therapy in elderly patients with atrial fibrillation considering risks of cerebral infarction and bleeding. <i>Scientific Reports</i> , 2023, 13, . | 1.6 | 0 |
| 83 | Chinese expert consensus on antithrombotic management of high-risk elderly patients with chronic coronary syndrome. <i>Aging Medicine (Milton (N S W))</i> , 2023, 6, 4-24. | 0.9 | 0 |
| 84 | Diagnostic and Therapeutic Strategies for Stable Coronary Artery Disease Following the ISCHEMIA Trial. <i>JACC Asia</i> , 2023, 3, 15-30. | 0.5 | 3 |
| 85 | Inappropriate Combined Antiplatelet and Anticoagulant Therapy in Older Patients with Atrial Fibrillation: Trend over Time (2009-18). <i>Drugs and Aging</i> , 2023, 40, 273-283. | 1.3 | 0 |
| 86 | Japanese high bleeding risk criteria status predicts low thrombogenicity and bleeding events in patients undergoing percutaneous coronary intervention. <i>Cardiovascular Intervention and Therapeutics</i> , 0, , . | 1.2 | 1 |
| 87 | Atrial fibrillation episode status and incidence of coronary slow flow: A propensity score-matched analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, . | 1.1 | 1 |
| 88 | Trends in antiplatelet strategies 12-months following coronary stent placement in anticoagulated patients. <i>BMC Cardiovascular Disorders</i> , 2023, 23, . | 0.7 | 0 |
| 89 | Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?. <i>PLoS ONE</i> , 2023, 18, e0283478. | 1.1 | 1 |
| 90 | Approach to atrial fibrillation. <i>Canadian Family Physician</i> , 2023, 69, 245-256. | 0.1 | 1 |
| 91 | Vasospastic angina in women: Clinical backgrounds and prognoses of patients younger than and older than 60 years. <i>World Journal of Cardiology</i> , 0, 15, 154-164. | 0.5 | 2 |